Swedish Orphan Biovitrum AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.02.21	Erste Schätzungen: Swedish Orphan Biovitrum AB präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
20.01.21	Doptelet® (avatrombopag) approved in the EU for treatment of ITP (PR Newswire)
20.01.21	Doptelet® (avatrombopag) approved in the EU for treatment of ITP (PR Newswire)
21.12.20	Sobi appoints new Head of North America ahead of launch phase (PR Newswire)
10.12.20	Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH (PR Newswire)
10.12.20	Emapalumab submission in China for primary HLH (PR Newswire)
10.12.20	Realising opportunities for future growth and financial update: Sobi Capital Markets Day 2020 (PR Newswire)
07.12.20	Agenda: Sobi Capital Markets Day 2020 (PR Newswire)
19.11.20	Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplan (PR Newswire)
06.11.20	Strong Sobi presence at American Society of Hematology 2020 Annual Meeting (PR Newswire)
04.11.20	Sobi launch Doptelet® (avatrombopag) in Europe (PR Newswire)
23.10.20	Invitation to the Sobi Capital Markets Day 2020 (PR Newswire)
22.10.20	Sobi publishes report for the third quarter 2020 (PR Newswire)
21.10.20	Ausblick: Swedish Orphan Biovitrum AB präsentiert Quartalsergebnisse (finanzen.net)
09.10.20	Sobi announces topline phase 3 data of avatrombopag for the treatment of Chemotherapy-Induced Thrombocytopenia (PR Newswire)
07.10.20	Invitation - Presentation of Sobi's Q3 2020 results (PR Newswire)
07.10.20	Erste Schätzungen: Swedish Orphan Biovitrum AB stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
23.09.20	First patient randomised in the phase 3 DISSOLVE clinical programme of SEL-212 for Chronic Refractory Gout (PR Newswire)
18.09.20	Orfadin® (nitisinone) receives positive opinion from CHMP for treatment of AKU (PR Newswire)
10.09.20	New England Journal of Medicine publishes positive final results from phase 1/2a study of BIVV001 in people with severe haemophilia A (PR Newswire)
18.08.20	Sobi appoints Dr Ravi Rao as new Head of Research & Development (PR Newswire)
15.07.20	Ausblick: Swedish Orphan Biovitrum AB gewährt Anlegern Blick in die Bücher (finanzen.net)
13.07.20	Data Presented at ISTH2020 Strengthens Evidence for Both Elocta® and Alprolix® in Previously Untreated Patients With Haemophilia (PR Newswire)
08.07.20	Data to be Presented at ISTH Virtual Congress Highlights Sobi's Commitment to Advancing Rare Haematology Treatments (PR Newswire)
06.07.20	Invitation - Presentation of Sobi's Q2 2020 Results (PR Newswire)
26.06.20	Successful Elocta Bid Means Increased Access for People With Haemophilia A in the UK (PR Newswire)
14.06.20	Sobi and Sanofi Donate up to 500 Million Additional IUs of Clotting Factor to WFH Humanitarian Aid Program (PR Newswire)
12.06.20	Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout (PR Newswire)
07.05.20	Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine (PR Newswire)
28.04.20	Ausblick: Swedish Orphan Biovitrum AB stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
22.04.20	Invitation - Presentation of Sobi's Q1 2020 Results (PR Newswire)
22.04.20	Sobi™ Affiliate Florio GmbH, Launches a New Digital Platform Aiming to Improve the Lives of People with Haemophilia (PR Newswire)
20.04.20	Sobi Offers Advance Voting at the 2020 Annual General Meeting (PR Newswire)
17.04.20	New Data Shows Varied State of Haemophilia Treatment Around the World: Sobi (PR Newswire)
14.04.20	Erste Schätzungen: Swedish Orphan Biovitrum AB stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
13.04.20	Sobi Sees Strong Revenue and EBITA Growth in the First Quarter 2020 (PR Newswire)
07.04.20	Sobi™ Publishes 2019 Annual and Sustainability Report (PR Newswire)
28.02.20	New Research Uncovers the Toll Rare Diseases Take on Relationships (PR Newswire)
13.02.20	Sobi Publishes Report for the Fourth Quarter and Full-year 2019 (PR Newswire)
12.02.20	Ausblick: Swedish Orphan Biovitrum AB zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
04.02.20	Invitation - Presentation of Sobi's Q4/FY 2019 Results (PR Newswire)
21.12.19	FDA Grants Avatrombopag Orphan Drug Designation for the Treatment of Chemotherapy-induced Thrombocytopenia (PR Newswire)
09.12.19	Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates (PR Newswire)
08.12.19	Results from a Survey With Patients With Immune Thrombocytopenia (ITP) Demonstrates Disease Burden and Impact for Patients With ITP (PR Newswire)
05.12.19	Data to be Highlighted at the American Society of Hematology 2019 Annual Meeting (PR Newswire)
12.11.19	Sobi Successfully Completes Acquisition of Dova Pharmaceuticals (PR Newswire)
10.11.19	Sobi Successfully Completes Tender Offer for All Outstanding Shares of Dova Pharmaceuticals (PR Newswire)
31.10.19	Sobi Publishes Report for Third Quarter 2019 (PR Newswire)
29.10.19	Ausblick: Swedish Orphan Biovitrum AB stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
23.10.19	Invitation - Presentation of Sobi's Q3 2019 Results (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Part Grp Hldg	1’244.50	1.34 %	K V
Geberit	523.40	1.32 %	K V
Roche Hldg G	253.60	1.00 %	K V
Novartis	92.38	0.90 %	K V
Sonova Hldg	306.60	0.86 %	K V
Givaudan	3’936.00	0.43 %	K V
Swisscom	507.50	0.40 %	K V
Zurich Insur Gr	549.00	0.26 %	K V
Swiss Life Hldg	728.40	0.17 %	K V
Nestle	75.98	0.03 %	K V

Nachrichten zu Swedish Orphan Biovitrum AB

Aktien Top/Flop

Meistgelesene Nachrichten